| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/30/2011 | US20110158936 Use of interleukin 17e for the treatment of cancer |
| 06/30/2011 | US20110158935 Substituted Diketopiperazine Analogs for Use as Drug Delivery Agents |
| 06/30/2011 | US20110158932 Methods And Compositions For The Treatment of Hyperlipidemia |
| 06/30/2011 | US20110158924 Photo-protective dermatological formulations |
| 06/30/2011 | US20110158910 Microparticles comprising polymers with thioester bonds |
| 06/30/2011 | US20110158908 Cyclosporin a-binding protein |
| 06/30/2011 | US20110158902 Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| 06/30/2011 | US20110155605 Apo-2 ligand |
| 06/30/2011 | CA2785139A1 Tetravalent cd47-antibody constant region fusion protein for use in therapy |
| 06/30/2011 | CA2785104A1 Topical ophthalmic peptide formulation |
| 06/30/2011 | CA2785021A1 Sustained-release formulation |
| 06/30/2011 | CA2784944A1 Synergic action of a prolyl protease and tripeptidyl proteases |
| 06/30/2011 | CA2784849A1 Amphiphilic polymer functionalised by methionine |
| 06/30/2011 | CA2783330A1 Herpes simplex virus vaccines |
| 06/30/2011 | CA2782796A1 Compositions and methods for the treatment of angiogenesis-related eye diseases |
| 06/30/2011 | CA2780080A1 Pharmaceutical compositions comprising igf-1 proteins, a buffering and a tonicity agent |
| 06/29/2011 | EP2339351A1 Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide |
| 06/29/2011 | EP2339035A1 Endogenous retroviruses up-regulated in prostate cancer |
| 06/29/2011 | EP2339020A1 Diagnostic methods based on Pregnancy-associated plasma protein-A (PAAP-A) |
| 06/29/2011 | EP2339014A1 Methods and compositions comprising non-natural amino acids |
| 06/29/2011 | EP2339013A1 Methods for producing modified glycoproteins |
| 06/29/2011 | EP2339003A2 APO-2 ligand substitutional variants |
| 06/29/2011 | EP2339002A1 Fibroblast growth factor homologs |
| 06/29/2011 | EP2338994A1 Regulation of oncogenes by microRNAs |
| 06/29/2011 | EP2338915A2 Anti-VEGF antibodies |
| 06/29/2011 | EP2338910A1 Cytokine receptor Zcytor17 multimers |
| 06/29/2011 | EP2338908A1 Peptides containing post-translational modifications and their use in the treatment of autoimmune pathologies |
| 06/29/2011 | EP2338904A1 Nisin derivatives and the use thereof |
| 06/29/2011 | EP2338900A1 A method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby |
| 06/29/2011 | EP2338899A1 Peptides for activation and inhibition of delta PKC |
| 06/29/2011 | EP2338897A1 Peptides and compounds that bind to a thrombopoietin receptor |
| 06/29/2011 | EP2338894A1 Flavivirus fusion inhibitors |
| 06/29/2011 | EP2338524A1 Combined gene therapy for the treatment of macroscopic gliomas |
| 06/29/2011 | EP2338522A1 Antitumoural therapies |
| 06/29/2011 | EP2338518A1 Specific therapy using integrin ligands for treating cancer |
| 06/29/2011 | EP2338516A2 Multiple-variable dose regimen for treating TNF-alpha-related disorders |
| 06/29/2011 | EP2338514A1 Combined human IL-18 and pazopanib cancer treatment |
| 06/29/2011 | EP2338513A2 Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| 06/29/2011 | EP2338508A1 A rDEN3/4delta 30(ME), rDEN2/4delta30(ME) or rDEN1/4delta30(ME) recombinant chimeric dengue virus containing a 30 nucleotide deletion (delta30) in a section of the 3' untranslated region of dengue type 4 genome, wherein said 30 nucleotide deletion corresponds to the TL2 stem-loop structure. |
| 06/29/2011 | EP2338506A2 Combinations of tumor-associated antigens for the treatment of various types of cancers |
| 06/29/2011 | EP2338505A2 Vault and vault-like carrier molecules |
| 06/29/2011 | EP2338504A2 Vault and vault-like carrier molecules |
| 06/29/2011 | EP2338503A1 Composition for improving brain function and method for improving brain function |
| 06/29/2011 | EP2338502A1 Composition for improving brain function and method for improving brain function |
| 06/29/2011 | EP2338501A1 Composition for improving brain function and method for improving brain function |
| 06/29/2011 | EP2338498A1 Compositions for the inhibition of protein kinase C alpha for the treatment of diabetes mellitus |
| 06/29/2011 | EP2338490A2 Combinations Useful for the Treatment of Neuronal Disorders |
| 06/29/2011 | EP2338448A2 Anti-inflammatory and antimicrobial uses for bioactive glass |
| 06/29/2011 | EP2338056A2 Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides |
| 06/29/2011 | EP2337868A1 Detection of granulosa-cell tumors |
| 06/29/2011 | EP2337849A1 Factor ix polypeptide mutant, its uses and a method for its production |
| 06/29/2011 | EP2337796A1 Recombinant proteins having haemostatic activity and capable of inducing platelet aggregation |
| 06/29/2011 | EP2337792A1 Polypeptides having antimicrobial activity |
| 06/29/2011 | EP2337580A1 New protecting compositions for recombinantly produced factor viii |
| 06/29/2011 | EP2337579A1 Cancer treatments with radiation and immunocytokines |
| 06/29/2011 | EP2337578A2 Composition and methods for modulating toll-like receptor activity |
| 06/29/2011 | EP2337577A1 Use of pituitary adenylate cyclase-activating polypeptide (pacap) and pacap analogs as adjunctive treatments with anticancer agents |
| 06/29/2011 | EP2337576A1 Treatment of mood and anxiety disorders |
| 06/29/2011 | EP2337575A1 Methods of treatment using single doses of oritavancin |
| 06/29/2011 | EP2337574A2 Anti-fungal therapy |
| 06/29/2011 | EP2337573A1 Whey and thymus function |
| 06/29/2011 | EP2337572A1 Nutritional composition to promote healthy development and growth |
| 06/29/2011 | EP2337571A1 Methods for determining the bioactivity of tgf-beta in a composition |
| 06/29/2011 | EP2337570A1 Compositions and methods for inhibiting entry of a hepatic virus |
| 06/29/2011 | EP2337568A1 Methods and means for soft tissue engineering |
| 06/29/2011 | EP2337558A1 Nutritional composition to promote healthy development and growth |
| 06/29/2011 | EP2231120B1 Solid lipid microcapsules containing growth hormone in the inner solid core |
| 06/29/2011 | EP1970382B1 Activated collagen scaffold materials and their special fused active restoration factors |
| 06/29/2011 | EP1944037B1 Remedy for mastitis |
| 06/29/2011 | EP1861419B1 Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
| 06/29/2011 | EP1737493B1 Inhibitors of insulin-like growth factor receptor -1 for inhibiting tumor cell growth |
| 06/29/2011 | EP1730142B1 Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus |
| 06/29/2011 | EP1658097B1 Nucleotide and cellular vaccine composition |
| 06/29/2011 | EP1537142B1 Akap18 delta, a novel splicing variant of a protein kinase a anchor protein and the use of the same |
| 06/29/2011 | EP1503788B1 Treatment of alpha-galactosidase a deficiency |
| 06/29/2011 | EP1497321B1 Immunological methods and compositions for the treatment of alzheimer's disease |
| 06/29/2011 | EP1183348B1 Compositions for the treatment and diagnosis of breast cancer and methods for their use |
| 06/29/2011 | EP1114151B1 G protein-coupled receptor antagonists |
| 06/29/2011 | CN1989963B Pharmaceutical compositions |
| 06/29/2011 | CN1918298B Pharmaceutical composition and method of treatment of human malignancies with arginine deprivation |
| 06/29/2011 | CN1835769B KIM-1 antagonists and use to modulate immune system |
| 06/29/2011 | CN1427889B Hybrid cells obtainable from antigen presenting cells |
| 06/29/2011 | CN102112612A Variant hhip1 protein and methods and uses thereof |
| 06/29/2011 | CN102112488A Vaccine against amyloid folding intermediate |
| 06/29/2011 | CN102112149A Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases |
| 06/29/2011 | CN102112148A Use of cell-permeable peptide inhibitors of jnk signal transduction pathway for treatment of chronic or non-chronic inflammatory digestive diseases |
| 06/29/2011 | CN102112147A XBP1, CD138, and CS1 peptides |
| 06/29/2011 | CN102112146A Immunity inducer |
| 06/29/2011 | CN102112145A Suppression of neuroendocrine diseases |
| 06/29/2011 | CN102112144A Targeted coagulation factors and method of using the same |
| 06/29/2011 | CN102112125A Antibacterial combination therapy for the treatment of gram positive bacterial infections |
| 06/29/2011 | CN102112109A Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer |
| 06/29/2011 | CN102112107A Controlled release copolymer formulation with improved release kinetics |
| 06/29/2011 | CN102112008A Particles of collagen material and process the preparation |
| 06/29/2011 | CN102108351A Low-immunogenicity staphylokinase mutant and preparation method and use thereof |
| 06/29/2011 | CN102108350A Preparation method of bromelin |
| 06/29/2011 | CN102108346A Method for preparing lysozyme |
| 06/29/2011 | CN102108098A Crocodile collagen, and preparation and use thereof |
| 06/29/2011 | CN102108097A Novel GLP-1 (glucagon-like peptide-1) derivative |
| 06/29/2011 | CN102107008A DNA damage repair inhibitors for treatment of cancer |